Can a simple blood test make a key transplant drug safer?
NCT ID NCT05711732
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study collects blood samples from children and adults receiving the chemotherapy drug busulfan before a stem cell transplant. The goal is to compare a new, faster test with standard lab methods for measuring drug levels in the blood. If the new test works well, it could help doctors adjust each patient's dose to avoid toxic side effects or underdosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- busulfan (the drug being monitored, not tested as an intervention)
- What this could lead to
- If the new test proves accurate, doctors could personalize busulfan doses for each patient, potentially reducing side effects and improving transplant outcomes.
- What could go wrong
- This is an early method-comparison study, not a treatment trial. The test may not prove reliable enough for routine use, and no direct patient benefit is guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT HEMATOLOGIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
ACTIVE_NOT_RECRUITINGChicago, Illinois, 60611, United States
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08903, United States
-
The University of Texas MD Anderson Cancer Center
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.